Abstract
Despite the broad spectrum of acute coronary syndrome, the benefits and risks of prolonged dual antiplatelet therapy (DAPT) according to initial presentation with or without myocardial infarction (MI) have not been well studied. In the SMART-DATE trial, 12-month or longer DAPT, when compared with 6
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
